Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02575833 · ClinicalTrials.gov registry record · Phase 2
Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT02575833 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 89 participants.
The verdict
NCT02575833, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
A phase 2a, multicenter, randomized, double-blind, placebo-controlled study in adults with stable angina to evaluate the effect of erenumab (AMG 334) compared to placebo on exercise time during an exercise treadmill test.
Interventions
- DRUG Placebo
- DRUG Erenumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2015-11-23 |
| Est. Completion | 2017-04-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02575833
The ClinicalTrials.gov registry entry for NCT02575833 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02575833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02575833 about?
NCT02575833 is a clinical study titled "Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)". A phase 2a, multicenter, randomized, double-blind, placebo-controlled study in adults with stable angina to evaluate the effect of erenumab (AMG 334) compared to placebo on exercise time during an exercise treadmill test.
What is the current status of trial NCT02575833?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2015-11-23. Estimated completion is 2017-04-13.
What interventions are being tested in trial NCT02575833?
The interventions under investigation include: Placebo (DRUG), Erenumab (DRUG).
Who is sponsoring clinical trial NCT02575833?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.